Efficacy and safety of the oral PCSK9 macrocyclic peptide inhibitor MK-0616: a phase 2b randomized controlled trial

Alberico L. Catapano

Professor of Pharmacology and Director of the Center of Epidemiology and Preventive Pharmacology at the University of Milan

Cookies
We use cookies. If you think that's OK, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. You can change your settings from our Cookie Policy page.
Save Accept all

Report

Contains abusive or derogatory content
Contains mature or sensitive content
Contains misleading or false information
Contains spam, fake content or potential malware
Harassment or bullying behavior

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .